TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01047527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal nicotine patch
Description: Transdermal nicotine, 21mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Description: Transdermal nicotine, 21mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal nicotine patch
Description: Transdermal nicotine, 21mg/day
Study: NCT04099004

Intervention type: OTHER
Group type: OTHER
Intervention: Neural Imaging
Description: During the acquisition of magnetic resonance (MR) images, the study participants will lie on the scanner table. For most portions of MR acquisition, the study participants will be instructed to lie still. For other parts of the acquisition, study participants will be asked to complete a combined knee and hip flexion/extension movement and a quadriceps contraction task in which they will be asked to 'squeeze' their quadriceps while keeping the rest of their body still. For the last 15 minutes of MR acquisition, the researcher will place one hand above the participants' knee and apply intermittent pressure to their quadriceps and medial aspect of the patella. Pain scales will be administered after every fMRI task to assess subjective perceptions of pain. Peripheral pulse oximetry and respiration waveforms will be collected for data analysis in order to minimize the potential confounding effect from the physiological changes.
Study: NCT01349816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: PT003 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: PT003 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: PT003 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001
Description: PT001 MDI administered as two puffs BID for 7 days
Study: NCT01139177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting of atherosclerotic lesion(s)
Description: Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
Study: NCT02523781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: information pamphlet
Description: The intervention group receives the information pamphlet
Study: NCT01147354

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium yeast
Description: The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: The patients in this arm took one placebo capsule daily for 12 weeks.
Study: NCT03548467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.NEO
Description: VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.NEO
Description: VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin
Description: 0.006 mg/kg bempegaldesleukin (NKTR-214) will be administered intravenously q4w for up to 11 doses starting from week 11 or at any dosing visit up to week 34 and for up to week 50 (up to 11 doses). The first 2 doses will be in a Q3W interval and following doses in Q4W intervals.
Study: NCT01349816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005
Description: PT005 MDI administered as two puffs BID for 7 days
Study: NCT02074059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant for Inhalation
Description: Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant for Inhalation
Description: Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant for Inhalation
Description: Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
Study: NCT04524676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized Treatment
Description: Patients under evaluation including hepatic venous pressure gradient (HVPG) and contrast-enhanced computed tomography of portal venous. For those patients with a HVPG ≥12mmHg or with extraluminal para-gastric vein will under transjugular intrahepatic portosystemic shunt and others receive endoscopic treatment.
Study: NCT04620265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antigravity treadmill training 100% weight bearing
Description: This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
Study: NCT02074059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant for Inhalation
Description: Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant for Inhalation
Description: Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP alone
Description: nCPAP therapy
Study: NCT02626078

Intervention type: OTHER
Intervention: observation and interview of residents
Description: Residents will be observed during lunch to evaluate their behavior, verbal interactions between residents. The food intake during 24 hours will be evaluated also. In an interview after lunch, the appreciation of the meal by residents will be assessed by a questionnaire and the score of the nutritional state will be defined.
Study: NCT01500538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag and Vorinostat
Description: 4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)
Study: NCT02173158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Study: NCT02082210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emibetuzumab
Description: Administered Intravenously (IV)
Study: NCT04040725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib
Description: Rogaratinib is an oral drug that inhibits FGFR. Mutations in FGFR help bladder cancer grow.
Study: NCT02082210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emibetuzumab
Description: Administered Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered Intravenously (IV)
Study: NCT00544258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Study: NCT03365596

Intervention type: OTHER
Intervention: Conventional therapy
Description: According to the status of a patient, optimized therapy will be applied.
Study: NCT02253212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoCloud
Description: SonoCloud : dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
Study: NCT04620265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antigravity treadmill training 75% weight bearing
Description: This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
Study: NCT02479152

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LUCAS2 AD
Description: LUCAS™ 2AD with compressions like the standard LUCAS™ 2 but added decompressions above the initial start position.

Intervention type: DEVICE
Group type: OTHER
Intervention: LUCAS2 AD
Description: LUCAS™ 2AD with compressions like the standard LUCAS™ 2 but added decompressions above the initial start position.
Study: NCT01878201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: Fimasartan 30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 80 mg
Study: NCT03375541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Aversion Calculator
Description: The calculator asks the participant to rate their level of aversion to having a set list of potential medication side effects (0 = no concern; 1 = mild concern; 2 = moderate concern; 3 = moderate to severe concern; 4 = severe concern)
Study: NCT04898751

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor (ICI)
Description: Immune checkpoint inhibitors included were targeting either PD-1, PD-L1 or CTLA-4, and had received FDA approval at the time of study (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32), and Cemiplimab (L01XC33).
Study: NCT00277212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine + Aripiprazole
Description: Tablets, Oral, once daily, Phase 1 (all subjects) - up to 24 weeks; Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~Aripiprazole 10-30 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lamotrigine + Placebo
Description: Tablets, Oral, once daily, Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~placebo 0 mg/day
Study: NCT01727141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAB149
Description: QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVA237
Description: NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Study: NCT03924258

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iron status testing
Description: Blood sample for iron status testing
Study: NCT02721316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supported with intensive nursing follow post hospitalization
Description: Intensive nursing follow post - hospitalization
Study: NCT04366622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg riociguat as an immediate-release (IR) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg riociguat as an immediate-release (IR) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg riociguat as an immediate-release (IR) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg riociguat as an immediate-release (IR) tablet
Study: NCT04620265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antigravity treadmill training 50% weight bearing
Description: This group received antigravity treadmill training 50% weight bearing and conventional exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antigravity treadmill training 25% weight bearing
Description: This group received antigravity treadmill training 25% weight bearing and conventional exercise program.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: The conventional exercise program
Description: This group received the conventional exercise program only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The conventional exercise program
Description: This group received the conventional exercise program only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The conventional exercise program
Description: This group received the conventional exercise program only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The conventional exercise program
Description: This group received the conventional exercise program only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The conventional exercise program
Description: This group received the conventional exercise program only.
Study: NCT00307489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir DF
Description: 300 mg tablet, once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine /tenofovir DF
Description: emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
Study: NCT03361202

Intervention type: OTHER
Intervention: blood sampling
Description: * atrial fibrillation group:before Percutaneous Occluding of the Left Atrium, at hospital discharge and at J45 follow up~* control group:before coronary angiography and at hospital discharge.

Intervention type: OTHER
Intervention: blood sampling
Description: * atrial fibrillation group:before Percutaneous Occluding of the Left Atrium, at hospital discharge and at J45 follow up~* control group:before coronary angiography and at hospital discharge.
Study: NCT03342885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific sleep ergonomics guidance
Description: Participants receive a detailed instruction in sleep ergonomics. Participants are instructed to maintain either side lying or supine sleeping posture, depending on which is less painful. Neutral position of spine supported by specific placement of body pillow. Changing of posture during sleep is prevented. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General sleep ergonomics guidance
Description: Participants are instructed find most comfortable sleeping posture by personal preference and to avoid painful posture. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
Study: NCT00763074

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard life style modification for type 2 diabetes
Description: Two session of education for exercise and diet.~----------- Exercise: 30min/day x 4/week Diet: ideal body weight x 30\~35kcal/day
Study: NCT01343121

Intervention type: OTHER
Group type: OTHER
Intervention: sample collection
Description: Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: sample collection
Description: Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine

Intervention type: OTHER
Group type: OTHER
Intervention: Sample Collection
Description: Quality of Life (QOL) questionnaires given to the patient at each visit
Study: NCT00763074

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet restriction
Description: Education for diet and exercise every 2 weeks~----------- Dietary calorie restriction: reduce their usual intake by -500kcal/day
Study: NCT01529034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL261
Study: NCT02087111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: 375 mg film coated tablets
Study: NCT00241371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Study: NCT02488265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance training with rhythmical (BRT), is a motor program to improve balance associated with rhythmical auditory cues (RACs).
Study: NCT00763074

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Education for diet and exercise every 2 weeks~----------- Exercise: more than 60min/day of exercise with moderate activity level twice per day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and exercise
Description: Education for diet and exercise every 2 weeks~----------- Exercise education like as exercise group and diet education like as diet group
Study: NCT01855295

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplement
Description: During the treatment phase, study subjects are advised to increase protein intake to 1.2 g/kg/day for 12 weeks. In addition to any protein supplementation the participant is on, supervised supplementation on each dialysis session is provided. Each participant receives 45 grams of liquid protein supplement (Provide Sugar Free produced by Provide Nutrition LC) at each dialysis treatment for additional 12 weeks for total study duration of 24 weeks.
Study: NCT04830527

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMA prompting for patients
Description: EMA prompting will consist of the delivery of the PHQ-4 and PANAS questionnaires, as well as basic identification, therapy motivations and expectations, location, current activity and social interactions.~These prompts will be presented to patients during a 7 day period, 5 times per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMA prompting for patients
Description: EMA prompting will consist of the delivery of the PHQ-4 and PANAS questionnaires, as well as basic identification, therapy motivations and expectations, location, current activity and social interactions.~These prompts will be presented to patients during a 7 day period, 5 times per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDF Reports for therapists
Description: After the patients' EMA data is collected, a previously designed R script will summarize and transform the data into a brief and graphic report for therapists in the experimental arm of the study. These reports are intended to provide detailed information about the patients' mood, anxiety levels, positive and negative affects, as well as crossed data such as mood according to location, anxiety according to activity, etc.
Study: NCT00398853

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chromium picolinate 1000 mcg daily vs placebo
Description: chromium picolinate 1000 mcg daily vs placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study: NCT02975921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Intrapleural administration of Povidone-Iodine
Study: NCT02488265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance training with rhythmical (BRT), is a motor program to improve balance associated with rhythmical auditory cues (RACs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening to prevent falls
Description: Questionary to Scheduled screening falls and progression in training will be used to indicate the capacity to continue to progress.
Study: NCT01039896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period I : SLM0807, Period II : HKB0701 and SLM0807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period I : HKB0710 and SLM0807, Period II : SLM0807
Study: NCT03594097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment cookies
Description: Plain flour, Coconut Nourish, Queen Garnet Plum, Unsalted Butter, Artificial Sweetener

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control cookies
Description: Plain flour, Coconut Powder, Unsalted Butter, Artificial Sweetener, Food Colour
Study: NCT02087111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 Kd Pegylated interferon alfa 2a
Description: 180 µg in pre-filled syringe for sub-cutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablets
Study: NCT03715244

Intervention type: PROCEDURE
Intervention: Spinal anesthesia with short-acting local anesthetics
Description: Spinal anesthesia in patients with duration of surgery \< 90 minutes
Study: NCT02488265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening to prevent falls
Description: Questionary to Scheduled screening falls and progression in training will be used to indicate the capacity to continue to progress.
Study: NCT05238246

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Behavioral guidance with tell-show-do
Description: The effect of tell-show-do technique during dental treatment on behavior in pediatric patients was evaluated and compared.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral guidance with robot
Description: The effect of the tell-show-do and distraction technique during dental treatment on behavior in pediatric patients was evaluated and compared.
Study: NCT02908815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS active treatment
Description: Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS active treatment
Description: Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.
Study: NCT03715244

Intervention type: PROCEDURE
Intervention: General anesthesia (current standard)
Description: General anesthesia in patients with duration of surgery \< 90 minutes
Study: NCT00587704

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PVB using nerve stimulation
Description: 5ml of 1% ropivacaine injected incrementally

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PVB using anatomic landmarks
Description: 5ml of 1% ropivacaine injected incrementally
Study: NCT03422497

Intervention type: OTHER
Intervention: Male sex
Description: Male sex-as listed in the discharge abstract database

Intervention type: OTHER
Intervention: Female sex
Description: Male sex-as listed in the discharge abstract database
Study: NCT03063281

Intervention type: OTHER
Intervention: BIological analysis
Description: Biological analysis : ficolin-2 et anti-ficolin-2 antibodies

Intervention type: OTHER
Intervention: BIological analysis
Description: Biological analysis : ficolin-2 et anti-ficolin-2 antibodies
Study: NCT04137458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological analysis
Description: Blood and salivary samples will be taken at inclusion and a psychiatric assessment will be carried out